Payment overview · 2025
General Payments
$209.44
11 reported records · 8 companies
Healthcare provider profile · identity verified
Brent A Savelli, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TIFTON, GA · NPI 1306878251
Verified facts
What the public records show
CMS Open Payments records show Brent A Savelli, MD received $209.44 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 25.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Viberzi by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.56 | 25.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.15 | 15.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.95 | 14.8% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.16 | 12.0% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $20.43 | 9.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.36 | 7.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.11 | 7.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.72 | 7.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $209.44 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.56 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 109 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Celecoxib | Celecoxib | 756 | 245 |
| Amlodipine Besylate | Amlodipine Besylate | 439 | 125 |
| Montelukast Sodium | Montelukast Sodium | 407 | 120 |
| Pantoprazole Sodium | Pantoprazole Sodium | 368 | 107 |
| Fluticasone Propionate | Fluticasone Propionate | 344 | 148 |
| Levothyroxine Sodium | Levothyroxine Sodium | 339 | 81 |
| Duloxetine Hcl | Duloxetine Hcl | 301 | 78 |
| Losartan Potassium | Losartan Potassium | 289 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 283 | 84 |
| Omeprazole | Omeprazole | 253 | 64 |
| Simvastatin | Simvastatin | 228 | 68 |
| Atorvastatin Calcium | Atorvastatin Calcium | 223 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 60 |
| Temazepam | Temazepam | 215 | 58 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 207 | 54 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 193 | 56 |
| Lisinopril | Lisinopril | 188 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 184 | 51 |
| Clonazepam | Clonazepam | 174 | 28 |
| Famotidine | Famotidine | 170 | 74 |
| Bupropion Xl | Bupropion Hcl | 159 | 45 |
| Furosemide | Furosemide | 155 | 57 |
| Sertraline Hcl | Sertraline Hcl | 152 | 40 |
| Potassium Chloride | Potassium Chloride | 149 | 48 |
| Azelastine Hcl | Azelastine Hcl | 148 | 73 |
| Azithromycin | Azithromycin | 143 | 112 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 46 |
| Tramadol Hcl | Tramadol Hcl | 136 | 47 |
| Eliquis | Apixaban | 132 | 27 |
| Alprazolam | Alprazolam | 127 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 111 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 111 | 29 |
| Ozempic | Semaglutide | 109 | 29 |
| Metformin Hcl | Metformin Hcl | 107 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 105 | 22 |
| Donepezil Hcl | Donepezil Hcl | 104 | 25 |
| Spironolactone | Spironolactone | 102 | 30 |
| Mounjaro | Tirzepatide | 100 | 16 |
| Prednisone | Prednisone | 100 | 35 |
| Propranolol Hcl Er | Propranolol Hcl | 100 | 31 |
| Gabapentin | Gabapentin | 97 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 28 |
| Glimepiride | Glimepiride | 90 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 89 | 72 |
| Methylprednisolone | Methylprednisolone | 88 | 62 |
| Meloxicam | Meloxicam | 85 | 32 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 84 | 53 |
| Trazodone Hcl | Trazodone Hcl | 84 | 22 |
| Zaleplon | Zaleplon | 84 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 20 |
| Carvedilol | Carvedilol | 80 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 22 |
| Lorazepam | Lorazepam | 71 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 20 |
| Synthroid | Levothyroxine Sodium | 67 | 13 |
| Finasteride | Finasteride | 66 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 36 |
| Pregabalin | Pregabalin | 63 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 62 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 61 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 15 |
| Allopurinol | Allopurinol | 53 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 51 | 18 |
| Metformin Hcl Er | Metformin Hcl | 51 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 31 |
| Estradiol | Estradiol | 47 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 12 |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Valsartan | Valsartan | 44 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 12 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 43 | suppressed |
| Ezetimibe | Ezetimibe | 42 | 14 |
| Naproxen | Naproxen | 42 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | 20 |
| Levofloxacin | Levofloxacin | 40 | 33 |
| Cephalexin | Cephalexin | 36 | 30 |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 15 |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 34 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 34 | suppressed |
| Hydrocortisone | Hydrocortisone | 34 | 18 |
| Fentanyl | Fentanyl | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 11 |
| Atenolol | Atenolol | 31 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 17 |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 30 | suppressed |
| Praluent Pen | Alirocumab | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 18 |
| Tdvax | Tetanus, Diphtheria Tox,adult | 29 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 19 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 27 | suppressed |
| Metronidazole | Metronidazole | 27 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Creon | Lipase/Protease/Amylase | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 24 | 24 |
| Clobetasol Propionate | Clobetasol Propionate | 24 | 12 |
| Primidone | Primidone | 24 | suppressed |
| Nadolol | Nadolol | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Colchicine | Colchicine | 21 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 13 |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 17 |
| Dexamethasone | Dexamethasone | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 13 |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Brilinta | Ticagrelor | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 16 | 11 |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Tacrolimus | Tacrolimus | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $209.44 · 11 records | Novo Nordisk Inc | Auvelity, EVENITY, OTEZLA, Ozempic, QULIPTA, Quviviq, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error